Adjusting survival time estimates in the presence of treatment switching /

Treatment switching can occur when patients in the control group of a clinical trial are allowed to switch onto the experimental treatment at some point during follow-up. Switching is common in clinical trials of cancer treatments and can also occur in trials of treatments for other diseases. When s...

Full description

Saved in:
Bibliographic Details
Online Access: http://www.ncbi.nlm.nih.gov/books/NBK310374/
Full text
Main Authors: Latimer, Nicholas (Author), Abrams, K. R. (Keith R.) (Author)
Format: Electronic eBook
Language:English
Published: London : National Institute for Health and Care Excellence (NICE), 2014
Series:NICE DSU technical support document ; 16.
Subjects:

MARC

LEADER 00000cam a2200000 i 4500
001 p2435400
005 20240212122426.0
006 m o d
007 cr bn ||||||||
008 190202s2014 enka ob 000 0 eng
035 |a (DNLM)BKSHLF:NBK310374 
035 |a 1741946 
040 |a DNLM  |b eng  |e rda  |c DNLM  |d UtOrBLW 
041 0 |a eng 
042 |a pcc 
060 0 0 |a WA 950 
100 1 |a Latimer, Nicholas,  |e author.  |0 nb2013008551 
245 1 0 |a Adjusting survival time estimates in the presence of treatment switching /  |c report by the Decision Support Unit ; Nicholas R Latimer, Keith R Abrams. 
264 1 |a London :  |b National Institute for Health and Care Excellence (NICE),  |c July 2014. 
300 |a 1 online resource (1 PDF file (57 pages)) :  |b illustrations. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a NICE DSU technical support document ;  |v 16 
504 |a Includes bibliographical references. 
520 3 |a Treatment switching can occur when patients in the control group of a clinical trial are allowed to switch onto the experimental treatment at some point during follow-up. Switching is common in clinical trials of cancer treatments and can also occur in trials of treatments for other diseases. When switching occurs, an "intention to treat" (ITT) analysis - whereby the data are analysed according to the arms to which patients were randomised - of the overall survival (OS) advantage associated with the new treatment will be biased: If control group patients switch treatments and benefit from the new treatment the OS advantage of the new treatment will be underestimated. Various statistical methods are available to adjust survival estimates in the presence of treatment switching, but each makes important assumptions and is subject to limitations. This Technical Support Document (TSD) introduces Rank Preserving Structural Failure Time Models (RPSFTM), Iterative Parameter Estimation (IPE), Inverse Probability of Censoring Weights (IPCW) and other adjustment methods that may be used in the presence of treatment switching. 
588 |a Description based on online resource; title from PDF title page (viewed April 10, 2019). 
650 1 2 |a Survival Analysis.  |0 D016019 
650 2 2 |a Clinical Trials as Topic.  |0 D002986 
650 2 2 |a Control Groups.  |0 D035061 
650 2 2 |a Therapies, Investigational.  |0 D035703 
650 2 2 |a Intention to Treat Analysis.  |0 D057194 
650 2 2 |a Treatment Outcome.  |0 D016896 
700 1 |a Abrams, K. R.  |q (Keith R.),  |e author.  |0 nb 99066945  
710 2 |a National Institute for Health and Care Excellence (Great Britain).  |b Decision Support Unit,  |e issuing body.  |0 n 2019181846 
830 0 |a NICE DSU technical support document ;  |v 16.  |0 n 2019181951 
856 4 0 |u http://www.ncbi.nlm.nih.gov/books/NBK310374/  |t 0 
951 |a 2435400 
992 |p P2  |e EF  |a 20190202 
993 |a EXL  |b 20190226 
995 |a AUTH  |b 20190412  |c REV  |d 20190417 
998 |a BKSHLF  |b 20190202 
998 |a FER  |b 20190202 
999 |a AUTH 
999 f f |i f709bda3-e0b6-5817-a9f4-b742983a8e5f  |s 04083bb1-4bb0-50e3-bb87-7a4efdb3e45c  |t 0 
952 f f |a Massachusetts College of Pharmacy and Health Sciences  |b Online  |c Online  |d E-Collections  |t 0  |e NCBI  |h Other scheme 
856 4 0 |t 0  |u http://www.ncbi.nlm.nih.gov/books/NBK310374/  |y Full text